Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Basel, Switzerland

About this trial

The investigator hypothesize that low-dose MDMA (3,4-methylenedioxymethamphetamine) will produce a sufficiently strong oxytocin stimulation in healthy controls and no relevant increase in patients. This study will confirm previously published data and provide important safety data with low-dose MDMA stimulation testing.

Eligibility criteria

Qualifiers

Adult healthy controls

Matched for age, sex, Body mass index, and oestrogen replacement/menopause/hormonal contraceptives to patients

No medication, except hormonal contraception

Disqualifiers

Participation in a trial with investigational drugs within 30 days

Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months

Consumption of alcoholic beverages >15 drinks/week

Tobacco smoking >10 cigarettes/day

Trial design

Treatments tested in this trial

  • MDMA
  • Placebo

Treatment groups

24 Participants
are divided into 2 treatment groups